Permeation of Dopamine Sulfate through the Blood-Brain Barrier by Suominen, Tina et al.
RESEARCH ARTICLE
Permeation of Dopamine Sulfate through the
Blood-Brain Barrier
Tina Suominen1, T. Petteri Piepponen2, Risto Kostiainen1*
1 Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki,
Helsinki, Finland, 2 Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of
Helsinki, Helsinki, Finland
* risto.kostiainen@helsinki.fi
Abstract
Dopamine sulfate (DA-3- and DA-4-S) have been determined in the human brain, but it is
unclear whether they are locally formed in the central nervous system (CNS), or transported
into the CNS from peripheral sources. In the current study, permeation of the blood-brain
barrier (BBB) by DA-S was studied by injecting 13C6-labelled regioisomers of DA-S (
13DA-
3-S and 13DA-4-S) and dopamine (DA) subcutaneously (s.c.) in anesthetized rats, then
analyzing brain microdialysis and plasma samples by UPLC-MS/MS. The results in the
microdialysis samples demonstrated that brain concentrations of 13DA-S regioisomers
clearly increased after the s.c. injections. The concentration of DA did not change, indicating
the permeation of DA-S through an intact BBB. The analysis of plasma samples, however,
showed that DA-S only permeates the BBB to a small extent, as the concentrations in
plasma were substantially higher than in the microdialysis samples. The results also showed
that the concentrations of DA-3-S were around three times higher than the concentrations of
DA-4-S in rat brain, as well as in the plasma samples after the s.c. injections, indicating that
DA-3-S and DA-4-S permeate the BBB with similar efficiency. The fate of 13DA-S in brain was
followed bymonitoring 13C6-labelled DA-S hydrolysis products, i.e.
13DA and its common
metabolites; however, no 13C6-labelled products were detected. This suggests that DA-S
either permeates through the BBB back to the peripheral circulation or is dissociated or
metabolized by unexpected mechanisms.
Introduction
The monoamine neurotransmitters dopamine (DA) and serotonin (5-HT) are involved in sev-
eral physiological processes in the brain [1–3]. Both DA and 5-HT are metabolized by mono-
amine oxidase (MAO) to the phase I metabolites 3,4-dihydroxyphenylacetic acid (DOPAC)
and 5-hydroxyindoleacetic acid (5-HIAA), respectively. DOPAC is further metabolized to
homovanillic acid (HVA) by catechol-O-methyltransferase (COMT). Both DA and 5-HT, and
their respective metabolites, can undergo conjugation with glucuronic acid or sulfonate medi-
ated by catalysis with UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs),
respectively. The glucuronide and sulfate conjugates have been considered inactive, but
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recently the activity of glucuronide and sulfate conjugates of a few other substances has been
shown. For example, the glucuronide or sulfate conjugates of dehydroepiandrosterone, preg-
nenolone [4,5], and morphine [6] are thought to be more active than the parent compounds in
modulating their pharmacological effects in the central nervous system (CNS).
The pharmacological properties of the sulfonate conjugates of neurotransmitters are not
well known. Some pharmacological properties of DA-S have been reported: intraventricularly
injected DA-S has been shown to trigger severe convulsions in conscious rats, which did not
occur when unconjugated dopamine was administered [7,8]. DA-S has been shown to bind to
the GABA receptor, but not to the dopamine receptors (D1 or D2) [7,9]. The regioisomer DA-
3-S has also been shown to have an inhibitory effect on aldosterone secretion in bovine cells in
vitro [10].
The BBB is a physical and biochemical barrier between the blood and the brain, which pre-
vents entry into the brain of most drugs and endogenous compounds from the blood. Only
small lipophilic compounds can diffuse passively through the BBB, while other compounds are
usually able to cross the BBB only with the help of carrier proteins [11,12]. The BBB is formed
by the brain capillary endothelial cells, and in addition to this physical barrier there are several
transporter proteins located in the BBB, e.g. ATP-binding cassette (ABC) transporters such as
P-glycoprotein (P-gp), multidrug resistance proteins (MRP in humans; Mrp in rodents), breast
cancer resistance proteins (BCRP), and solute carriers (SLC:s), such as the organic anion-trans-
porting polypeptides (OATPs in humans, Oatps in rodents), that are involved in the regulation
of substances in the central nervous system and the brain [11,13–15]. Some sulfate conjugates
are known substrates of different OATP/Oatp-transporters, such as the steroid conjugates
estrone-3-sulfate, estradiol-17β-glucuronide, and dehydroepiandrosterone sulfate (DHEA-S)
[14,16]. DHEA-S has been shown to permeate the BBB with the help of these transporter-pro-
teins, although the transport is mainly from the brain to the blood [16,17]. The sulfonate con-
jugate of pregnenolone has also been shown to permeate the BBB [18].
Microdialysis is a reliable method to examine the physiological state of the brain, or to esti-
mate drug transport to the brain across the BBB. A probe is inserted into a specific brain area,
and sampling is accomplished by pumping a solution, isotonically matched to the medium
being sampled, slowly through the probe and collecting it for analysis. The dialysis membrane
is permeable to small molecules but not to macromolecules such as proteins. The small mole-
cules are sampled by the probe, because the levels of neurotransmitters and metabolites are
higher in the extracellular space than in the perfusion fluid [19,20]. The levels of most neuro-
transmitters in the brain are low and sensitive analysis techniques, such as mass spectrometry,
must be utilized.
Only recently, sensitive mass spectrometric methods have been developed for the detection
of intact phase II metabolites of monoamine neurotransmitters and neurosteroids in rodent
and human brains [21–25]. Intact glucuronide conjugates of DA and 5-HT, and sulfonate con-
jugates of their phase I metabolites DOPAC, HVA, and 5-HIAA have been found in rat brain
[24], and intact sulfates of 5-HIAA and DA in human brain [25]. Earlier analytical methods for
the identification of sulfate and glucuronide conjugates of neurotransmitters involved a hydro-
lysis step [26–28], and did not provide identification of the conjugates with absolute certainty
or information about the site of conjugation. Whether the determined sulfate and glucuronide
conjugates are locally formed in the brain or originate in peripheral sources is still unknown.
Low mRNA levels of the UGTs that are thought to be involved in the conjugation of DA and
5-HT (e.g. UGTs 1A6 and 2B7) have been reported in rat and human brain, which makes local
formation an alternative [29–31]. In addition, SULTs responsible for the sulfonation of cate-
cholamines have been found in human and rat brain [32]. However, the formation of DA and
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5-HT conjugates in peripheral organs and their transport to the brain through the blood-brain
barrier (BBB) cannot be ruled out.
The purpose of this work was to study the permeation of DA and its sulfonate conjugates,
the regioisomers dopamine-3-O-sulfate (DA-3-S) and dopamine-4-O-sulfate (DA-4-S),
through the BBB by subcutaneous (s.c.) injections of DA, DA-3-S, and DA-4-S, as well as
13C6-isotopically labeled DA-3-O-S (
13DA-3-S) and DA-4-O-S (13DA-4-S) in rats. The fate of
the injected compounds and their possible effects on the concentrations of dopamine, seroto-
nin, and their metabolites (Fig 1) were analyzed in rat brain microdialysis samples using ultra-
performance liquid chromatographic-tandem mass spectrometry (UPLC-MS/MS).
Materials and Methods
Reagents and standards
3,4-dihydroxyphenethylamine hydrochloride (DA) and 3-methoxy-4-hydroxy-phenylacetic
acid (HVA) were purchased from Sigma-Aldrich (St. Louis, MO). 5-hydroxytryptamine
(5-HT), 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindole-3-acetic acid
(5-HIAA), formic acid, and dimethyl sulfoxide-d6 (CD3SOCD3) were purchased from Sigma-
Aldrich (Steinheim, Germany). 13C6-labelled dopamine (
13DA) was purchased from C/D/N
isotopes, Quebec, Canada. Acetonitrile (ACN) was purchased from Rathburn (Walkerburn,
Scotland). Sulfuric acid (H2SO4, BDH, 98%) was used in the chemical synthesis of sulfate
conjugates. Isoflurane (Vetflurane, Virbac, France) was purchased from the University Phar-
macy, Helsinki, Finland. The phase II metabolites of 5-HT, DA, and their phase I metabolites
(Table 1), which were used as reference standards in this study, had been synthesized earlier in
our laboratory by the methods described in detail elsewhere [23,24,33].
Ringer’s solution, used for microdialysis and dilution of the standards, contained 147 mM
NaCl (Akzo Nobel, Denmark), 1.2 mM CaCl2 (J.T.Bakers, Deventer, The Netherlands),
Fig 1. Structures of dopamine and serotonin and their main metabolites.
doi:10.1371/journal.pone.0133904.g001
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2.7 mM KCl (Sigma-Aldrich, Steinheim, Germany), 1.0 mMMgCl2 (Riedel-de-Haehn AG,
Seelze, Germany), and 0.04 mM ascorbic acid (University Pharmacy, Helsinki, Finland).
Chemical synthesis of 13C6-dopamine sulfates
Cold concentrated H2SO4 (200 μL) was added to 20 mg of
13C6-DA HCl. The reaction mixture
was kept in ice for 20 minutes and then pipetted over 1 mL of frozen water. The pH of the reac-
tion mixture was adjusted to 3 with 5 M NaOH. The sulfates were fractionated using an Agilent
HP 1100 liquid chromatograph (Hewlett-Packard GmbH, Waldbronn, Germany) equipped
with a UV diode array detector and fraction collector. A Discovery HS F5 column (150 mm × 4
mm, 3 μm, Sigma-Aldrich, Bellefonte, PA) was used in the purification. Aqueous 0.1% formic
acid (A) and ACN containing 0.1% formic acid (B) were used as eluents. A gradient of 5% sol-
vent B from 0–1 min, 5–20% 1–11 min, 20–65% 11–12 min followed by 8 minutes equilibra-
tion was used for the fractioning of 13DA-3-S and 13DA-4-S. The 13DA-S regioisomers were
not completely baseline separated (RS = 1.0), and were fractionated together. The flow rate was
0.9 mL/min, and a wavelength of 275 nm was used for peak detection. The sulfate fractions,
containing both 13DA-3-S and 13DA-4-S, were evaporated to dryness under vacuum,
Table 1. The analytes, SRM transitions and validation data.
Linearity LOD LOQ Repeatability, n = 6
Rt ESI range S/N 3 S/N10 0.51/102/203/ 1004
Compound min SRM transitions +/- nM r2 nM nM nM (rsd %)
DA-G 1.81 330!137 (154, 91) + 0.5–20 0.995 0.1 0.5 13.01
DA 1.98 154!137 (119, 91) + 0.3–50 0.995 0.2 0.3 11.61
5-HT-G 2.69 353!160 (336, 177) + 0.2–2.5 0.996 0.1 0.2 8.01
5-HT 4.17 177!160 (115, 132) + 0.3–10 0.997 0.2 0.3 7.71
5-HT-S 5.23 257!240 (160, 115) + 1–100 0.999 0.4 1 2.62
5-HIAA-G 6.35 366!146 (131, 113) - 10–750 0.999 5 10 9.63
HVA-OH-G 6.74 357!193 (113, 175, 313) - 1–75 0.999 0.7 1 3.13
5-HIAA-S 8.18 270!226 (146, 80) - 10–500 0.996 5 10 11.63
5-HIAA 8.76 190!146 (144, 116) - 40–750 0.996 10 40 4.23
DA-4-O-S 2.68 232!152 (122) - 0.5–50 0.999 0.25 0.5 5.72
DA-3-O-S 2.82 232!152 (122) - 0.5–125 0.997 0.25 0.5 5.12
DOPAC-G 5.47 343!299 (123, 113) - 20–750 0.999 4 20 7.43
DOPAC 5.7 167! 123 (95) - 30–1000 0.998 20 30 6.74
DOPAC-S 5.99 247!203 (123, 80) - 10–500 0.998 5 10 nm
HVA-S 7.33 261!217 (202, 80) - 5–500 0.999 2.5 5 nm
HVA 9.35 181!137 (122, 105) - 30–1000 0.999 25 30 7.04
13C-DA-G 1.81 336!143 (160, 97) +
13C-DA 1.98 160!143 (125, 97) +
13C-DA-4-O-S 2.68 238!158 (128) -
13C-DA-3-O-S 2.82 238!158 (128) -
13C-DOPAC-G 5.47 349!305 (129, 113) -
13C-DOPAC 5.70 173! 129 (101) -
13C-DOPAC-S 5.99 253!209 (129) -
13C-HVA-G 6.74 363!193 (113, 175, 319) -
13C-HVA-S 7.33 267!223 (208, 80) -
13C-HVA 9.35 187!143 (128) -
The concentrations in the repeatability measurements were 0.5, 10, 20, or 100 nM presented as superscripts 1, 2, 3, or 4, respectively.
doi:10.1371/journal.pone.0133904.t001
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lyophilized and reconstituted in Ringer’s solution. The synthesis yield was 3.7 mg (15%). As
the yield was low, UPLC-MS was used for the confirmation of the structure of 13DA-3-S and
13DA-4-S. Unlabeled DA-3-S and DA-4-S were synthesized in the same manner, and the syn-
thesis products were characterized by UPLC-MS and NMR.
Rat brain microdialysis samples
Wistar rats were used at 8–12 weeks of age. The protocols were approved by the National Ani-
mal Experiment Board of Finland. The rats were housed in groups of four to five per cage and
had free access to chow and water. They were maintained under a 12:12 h light/dark cycle with
lights on from 06:00 to 18:00 at an ambient temperature of 20–22 °C before the experiments.
The animals were implanted with a guide cannula (BAS MD-2250, Bioanalytical Systems
Inc., IN) using a stereotaxic device (Stoelting, Wood Dale, IL) under isoflurane anesthesia
(4.5% during induction for 5 min and then 3.5% during surgery). The guide cannula was aimed
above the rat dorsal striatum (A/P +1.0, L/M 2.7, D/V-6.0) according to the atlas by Paxinos
andWatson [34]. The cannula was fastened to the skull with dental cement (Aqualox, Voco,
Germany). A microdialysis probe (BAS MD-2200, 2 mmmembrane, Bioanalytical Systems
Inc., IN) was inserted into the striatum through the guide cannula on the morning of the exper-
imental day. Thus, the coordinates of dialysis membranes within the striatal tissue were A/P
+1.0, L/M 2.7, D/V-6.0 –-8.0.
The collection of microdialysis samples with 30 min intervals (2.5 μL/min) began 1 h after
insertion of the probe. Two baseline samples were collected prior to the injection of a solution
of 10 mM DA and 10 mMDA-S (containing the regioisomers DA-3-S and DA-4-S) at a vol-
ume of 1 mL/kg body weight (animals 1–3), or 10 mM 13DA-S (containing the regiosisomers
13DA-3-S and 13DA-4-S) at a volume of 1 mL/kg body weight (animals 4–7). After the injec-
tions, microdialysis samples were collected for 3 hours. The microdialysis samples were stored
in a freezer (-70°C) before analysis with UPLC-MS/MS. The samples were injected as such
without sample pretreatment.
Plasma samples
Immediately after initiation of isoflurane anesthesia, a blood sample was collected from the
femoral vein (time-point 0 hours), after which a solution containing 10 mM DA-S (containing
the regioisomers DA-3-S and DA-4-S) at a volume of 1 mL/kg body weight was administered
by subcutaneous injection. A second blood sample was collected at 0.5 hours, and the final
trunk blood sample 1 hour after the DA-S injection. The blood samples were collected in capil-
lary tubes (Microvette CB 300, Sarstedt, Germany) and centrifuged at 4000 g for 10 minutes at
4°C. The supernatant was ultrafiltered (Vivaspin, 10 0000 MWCO PES, Vivascience AG, Han-
nover, Germany) at 8600 g for 35 min at 4°C prior to analysis by UPLC-MS/MS.
UPLC-UV and UPLC-MS/MS
The UPLC-MS/MS system used in the analysis consisted of an Aquity UPLC equipped with a
photodiode array UV detector (Waters, Milford, MA) coupled to an Agilent 6410 triple quad-
rupole (Agilent technologies, Santa Clara, CA). The column used was a pentafluorophenyl col-
umn (Thermo Scientific Gold PFP Hypersil, 2.1 x 150 mm, 1.9 μm). The eluents used were A:
aqueous 0.1% formic acid, and B: acetonitrile and 0.1% formic acid. The gradient used in the
analysis of the samples was: B 3% 0–1.5 min, 3–15% 1.6–12 min, 16–65% 13–13.2 min, and 3%
13.5 min, followed by an equilibration of 11.5 min with a total run time of 25 min. The flow
rate was 0.3 mL/min, and the column oven temperature was kept at 30°C. The injection volume
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was 15 μL. The flow from the UPLC was directed to waste for the first 2.1 minutes of the gradi-
ent to avoid contamination of the ion source by the salts of the Ringer’s solution.
The purity of the synthesized DA-S was determined by UPLC-UV using Empower 2 soft-
ware (Build 2154). The Agilent 6410 triple-quadrupole mass spectrometer with an electrospray
ion source was used for the verification of the structure of the synthesis products, and for the
analysis of the brain microdialysis samples. Nitrogen (Parker Balston N2-22 nitrogen genera-
tor, Parker Hannifin Corporation, Haverhill) was used as the nebulizer (40 psi), curtain (12 L/
min, 350°C), and collision gas. The fragmentor voltages and collision energies were optimized
for each compound, and Agilent MassHunter software versions B.04.00 (quantitative data
analysis) and B.03.01 (qualitative data analysis) were used for data acquisition and processing.
The quantitative analysis of the brain microdialysis samples was performed in selected reaction
monitoring (SRM) mode using positive or negative ion mode (Table 1). The method was vali-
dated in terms of linearity, limit of detection (LOD), limit of quantification (LOQ), specificity,
and repeatability for each compound.
NMR spectroscopy
The synthesized and purified compounds were analyzed by nuclear magnetic resonance
(NMR) on a Varian Mercury 300 MHz spectrometer (Varian, Palo Alto, CA). 1H-spectra were
recorded as solutions in DMSO-d6. Chemical shifts (δ) are given in parts per million (ppm) rel-
ative to the NMR solvent signal (DMSO-d6) 2.50 ppm. As the obtained amounts of
13DA-3-S
and 13DA-4-S were too low for reliable NMR analysis, unlabeled DA-3-S and DA-4-S were syn-
thesized in the same manner and used for NMR characterization.
Results and Discussion
13DA-sulfate synthesis
The yield of the chemical synthesis of the mixture of 13DA-3-O-S and 13DA-4-O-S was 3.7 mg
(15%). The purity of the sulfates was estimated by UPLC-UV (diode array detection), and the
resulting chromatograms showed over 98% purity. The structures of the synthesized com-
pounds were verified by UPLC-MS and UPLC-MS/MS using negative ion mode. The ion chro-
matograms showed two peaks, the MS spectra of which showed abundant [M-H]- ions at m/z
238 indicating the correct molecular weights of the synthetized 13DA-3-S and 13DA-4-S. The
product ion spectra of the [M-H]- showed abundant product ions [M-H-SO3]
- (m/z 158) and
minor fragments [M-H-CH2NH2]
- (m/z 128) and [SO3]
- (m/z 80). Based on UV detection, the
mixture of the 13DA-S regioisomers contained 53% of 13DA-4-S and 47% of 13DA-3-S. The
spectra of the DA-S regioisomers are in accordance with earlier reported NMR data [33] con-
firming sulfonation to the hydroxyl groups attached to carbons 3 and 4.
Characterization of dopamine sulfates by NMR. The sulfonation sites of the synthesized
DA-3- and DA-4-S were verified by NMR. The NMR spectrum was acquired from a mixture of
the regioisomers. The transitions are in accordance with earlier reported NMR data of the sepa-
rated regioisomers [33]. The structures of DA-3- and DA-4-S are presented in Fig 1.
DA-4-O-S: 1H NMR (300 MHz, DMSO-d6) δ 8.00 (br. s, approx.1H), 7.06 (d, J = 8.2 Hz,
1H, partially overlapping with DA-4 protons), 6.73 (d, J = 1.8 Hz, 1H), 6.64 (d, J = 8.1 Hz, 1H),
3.04–2.95 (m, 2H, overlapping with DA-4 protons), 2.76–2.70 (m, 2H, overlapping with DA-4
protons).
DA-3-O-S: 1H NMR (300 MHz, DMSO-d6) δ 8.00 (br. s, approx.1H), 7.05 (m, J = 2.2 Hz,
1H, partially overlapping with DA-3 protons), 6.83 (dd, J = 8.2, 1.8 Hz, 1H), 6.77 (d, J = 8.2 Hz,
1H), 3.04–2.95 (m, 2H, overlapping with DA-3 protons), 2.76–2.70 (m, 2H, overlapping with
DA-3 protons).
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UPLC-MS/MS method
The UPLC-MS/MS method was validated in terms of limits of detection (LOD, signal-to-noise
ratio (S/N) of 3) and limit of quantification (LOQ, S/N of at least 10), linearity, and repeatabil-
ity using standards diluted in Ringer’s solution (Table 1). The LODs for DA, 5-HT, and their
metabolites varied between 0.1 and 20 nM, indicating good sensitivity of the method and
measuring at the same level as presented earlier for these compounds [24,35]. The calibration
curves showed good linearity, r2 being higher than 0.995 for all the compounds. The repeatabil-
ity of the method was studied at different concentration levels (0.5, 10, 20, or 100 nM), corre-
sponding to the concentrations of the analytes determined in the brain microdialysis samples
(Table 1). The relative standard deviations (% RSD) were below 15%, indicating good repeat-
ability of the analysis. The validation results show that the UPLC-MS/MS method provided
direct and reliable analysis of the neurotransmitters, their phase I metabolites and their sulfate
and glucuronide conjugates. The 13C6-isotopically labeled compounds were identified and
quantified using the retention times, SRM transitions, and calibration curves of the corre-
sponding unlabeled compounds. The analytes in the brain microdialysates were detected by
comparing the retention times and the intensity ratios of at least two SRM pairs for each com-
pound (Table 1) to those of the standards prepared in Ringer’s solution.
Although the UPLC-MS/MS method itself showed good quantitative performance, the bio-
logical variation between the rats caused relatively large variations in the concentrations of
DA-S in the plasma and microdialysis samples between the rats. The relative standard devia-
tions were about 50–100% between the microdialysis samples (Table 2 and Fig 2) and 20–60%
between the plasma samples (Table 3).
Permeation of dopamine and dopamine sulfates through the BBB
Amixture containing DA-S (DA-3-S and DA-4-S, 1:1) 2.3 mg/kg and DA 1.5 mg/kg was injected
subcutaneously (s.c) and the levels in rat brain were measured by microdialysis samples collected
at 30 minutes intervals for 3 hours after administration (n = 3). By also injecting intact DA, the
function of the BBB was controlled, as DA does not permeate the BBB. In all three rats the con-
centrations of DA-3-S and DA-4-S were below the limit of detection before the injection, but
clearly increased 30 min after the injection (Fig 2). To confirm the results, the experiment was
repeated with a mixture of labelled 13DA-S regioisomers (2.4 mg/kg) (n = 4). Again, in all four
rats the concentrations of both 13DA-3-S and 13DA-4-S clearly increased 30 min after the s.c.
injection. In contrast to DA-S, the concentrations of intact DA did not change significantly after
the injection, measuring at the same levels as reported earlier in rat striatal microdialysis samples
(0.7–8 nM) [23,24,36]. These results clearly show that DA-S permeates the intact BBB.
In general, the concentrations of DA-S in rat brain microdialysis samples increased after the
s.c. injection, achieved maximum, and then decreased (Fig 2). The concentration profiles of
DA-3-S and DA-4-S were somewhat different: the concentrations of DA-3-S were on average
about three times higher than those of DA-4-S in all the brain microdialysis samples of the test
animals.
DA-S was also quantified in the rat plasma samples collected at the time-points of 0 (injection
of DA-S), 30 and 60 min corresponding to the same time points as in the microdialysis experi-
ments. The results showed that the DA-S concentrations in the plasma samples are about 1000
times higher than in the brain microdialysis samples (Tables 2 and 3) indicating that only a small
fraction of DA-S is passed through the BBB. Also the possibility that DA-S is transformed during
its diffusion to the microdialysis probe cannot be ruled out. As the concentrations of DA-3-S
were around 2–3 times higher than the concentrations of DA-4-S also in the plasma samples, this
indicates that DA-3-S and DA-4-S permeate the BBB with similar efficiency.
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The fate of DA-S in brain was followed by monitoring the possible hydrolysis and metabo-
lite products of dopamine and serotonin (Table 1). The monitoring of 13C6-labelled DA-S
products provides a selective method for the identification of the possible hydrolysis and
Table 2. Mean concentrations (nM) and standard deviations between the rats (see Fig 2) for DA-3-S, 13DA-3-S, DA-4-S and 13DA-4-S at the time-
points of microdialysis sampling.
DA-3-S
Timepoint (h) 0.5 1 1.5 2 2.5 3 3.5 4
Mean 0.00 0.00 1.75 4.00 4.36 3.75 3.32 2.77
Sd 0.00 0.00 0.82 0.80 0.72 0.61 0.76 1.06
Rsd % 47 20 17 16 23 38
13DA-3-S
Timepoint (h) 0.5 1 1.5 2 2.5 3 3.5 4
Mean 0.00 0.00 1.07 3.85 6.18 7.31 9.30 7.93
Sd 0.00 0.00 0.67 3.39 4.37 4.97 9.27 8.36
Rsd % 62 88 71 68 100 105
DA-4-S
Timepoint (h) 0.5 1 1.5 2 2.5 3 3.5 4
Mean 0.00 0.00 1.06 1.58 0.98 0.82 0.58 0.39
Sd 0.00 0.00 0.54 0.27 0.39 0.53 0.23 0.20
Rsd % 50 17 39 64 39 52
13DA-4-S
Timepoint (h) 0.5 1 1.5 2 2.5 3 3.5 4
Mean 0.00 0.00 0.86 2.06 1.81 1.39 1.15 0.88
Sd 0.00 0.00 0.78 2.02 0.99 0.95 1.38 0.85
Rsd % 91 98 54 68 119 97
doi:10.1371/journal.pone.0133904.t002
Fig 2. Concentrations of non-labeled and 13C6-labelled DA-3-S and DA-4-S in rat brain microdialysates after s.c. injections.
doi:10.1371/journal.pone.0133904.g002
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metabolite products based on the 13C6-labelled benzene moiety. However, the
13C-labelled
products presented in Table 1 were not detected in any of the brain microdialysis samples.
These results suggest that DA-S permeates the BBB back to the peripheral circulation, or is
metabolized by an unexpected mechanism producing metabolites which were not monitored.
The concentration profiles of naturally occurring (non-labelled) dopamine, serotonin, and
their metabolism products (Table 1) were studied by microdialysis samples collected before
and after the injection of 13C6-labelled DA-S. The basal concentrations of the naturally occur-
ring analytes (Table 4) measured before the injections are in accordance with earlier published
values for rat brain microdialysis samples collected from freely moving rats [23,24,37,38], even
though this experiment was performed with anesthetized rats.
The concentrations of the naturally occurring non-labelled metabolites of dopamine (DA-
G, DOPAC, DOPAC-S, HVA and HVA-S) increased after the injections of 13C6-labelled
DA-S. No clear trend in the levels of DA could be observed. Serotonin (5-HT) and its metabo-
lites followed a similar trend: while the 5-HT levels decreased in all animals during the experi-
ment, the concentrations of its metabolites (5-HT-G, 5-HIAA and 5-HIAA-S) increased
during the experiment (Fig 3). The injected 13DA-S may affect the metabolism process of natu-
rally occurring dopamine and/or other neurotransmitters, but anesthesia itself might also have
an impact on the concentration changes. The influence of volatile anesthetics on neurotrans-
mitter levels have been reported earlier: isoflurane has been shown to lower 5-HT levels in rats
and mice compared to levels during wakefulness [39,40]. Isoflurane anesthesia has also been
shown to increase DA levels at high doses (3% isoflurane), while the levels of DOPAC and
Table 3. Concentrations of DA-3-S and DA-4-S in plasma samples (nM) before (0 min) and after s.c. injections (30 and 60min).
DA-3-S DA-4-S
0 min 30 min 60 min 0 min 30 min 60 min
Rat 1 11.4 14600 10830 0.0 5340 4000
Rat 2 nm 17760 7680 nm 10340 2950
Rat 3 4.9 13200 9900 2.6 6280 2630
mean 8.2 15200 9470 1.3 7320 3180
sd 4.6 2320 1620 2660 692
rsd % 57 15 17 36 22
doi:10.1371/journal.pone.0133904.t003
Table 4. Basal concentrations (nM) of the neurotransmitters and their metabolites in rat brain microdialysis samples before the injection. The con-
centrations are the average values of the first two time points (0.5 and 1 h) in the experiments.
Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6
5-HT 0.39 0.23* 0.57 1.66 < LOD 0.28
5-HT-G 0.29 0.27 0.17 0.23 0.18 < LOD
5-HIAA 50.4 56.8* 91 101 96.9 102
5-HIAA-S 7.81 10.3 12.9 12.0 11.2 14.4
DA 1.95 0.92 0.79 0.68 0.69 0.63
DA-G 0.24* 0.22* 0.13* 0.17* < LOD < LOD
HVA 249 232 394 nm 430 428
HVA-S 35.4 41 85.4 nm 76.5 74.9
DOPAC 387 222 579 nm 511 401
DOPAC-S 166 151 283 nm 243 198
* = concentration below LOQ, estimated by extrapolation of the standard curve. nm = not measured
doi:10.1371/journal.pone.0133904.t004
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HVA increased at all isoflurane concentrations studied [41,42]. Similar effects have been
reported for halothane and sevoflurane [43,44]. Based on the literature it seems likely that the
fluctuations in neurotransmitter levels are due to anesthesia. Moreover, the isoflurane concen-
trations had to be slightly adjusted during the experiments, which additionally might have
influenced the neurotransmitter levels. However, this does not rule out that the injected DA-S
might also have contributed to these level changes.
Conclusions
The peripheral injections of 13C-labelled DA-S followed by analysis of brain microdialysis sam-
ples by UPLC-MS/MS provide a reliable method to study the permeation of DA-S through the
BBB. The study clearly shows that DA-S, but not DA, is able to permeate the BBB of rats. The
result is interesting, since DA-S is more polar than DA and the passive permeation of DA-S
through the BBB is not obvious. Therefore, it can be concluded that DA-S most likely perme-
ates the BBB by binding to an active transporter-protein located in the BBB. However, the con-
centrations of DA-S in the plasma samples after its subcutaneous injection were about 1000
times higher than the concentration in the brain microdialysis samples. Based on the fairly
high concentrations in the plasma samples, it is clear that only a small amount of the DA-S in
plasma permeates the BBB. However, the results still show that DA-S crosses the BBB but DA
itself does not.
Even though the results show that DA-S crosses the BBB, no information on the fate of the
permeated DA-S in the brain was acquired. The results showed that DA-S is not hydrolyzed to
DA or transformed into any common metabolites of DA with concentrations above the limits
of detection of this method. It is therefore possible that DA-S is metabolized by an unexpected
mechanism or is pumped out of the brain by active transporters. However, these results
obtained from experiments with rats cannot be directly applied to humans. DA-S has earlier
been found in human brain microdialysis samples [25] but not in rat brain microdialysis
Fig 3. Concentrations of the neurotransmitters (Left: dopaminemetabolites, right: serotoninmetabolites) during the test in rat brain
microdialysates in one of the test animals (Rat 6).
doi:10.1371/journal.pone.0133904.g003
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samples, indicating that the concentration of DA-S in human brain is significantly higher than
in rat brain. DA-S can be assumed to be biologically less active than DA providing a source for
free DA in brain through enzymatic hydrolysis. Therefore, the study of the permeation of
DA-S through the human BBB and the fate of DA-S in human brain is of great interest.
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